A Double-Masked, Randomised, Placebo-Controlled, Parallel-Group, 12 Week, Phase 2 Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Patients With Fuchs Endothelial Corneal Dystrophy
Latest Information Update: 07 Nov 2024
At a glance
- Drugs Ripasudil (Primary)
- Indications Fuchs' endothelial dystrophy
- Focus Therapeutic Use
- Sponsors Kowa Research Institute
Most Recent Events
- 31 Aug 2022 Status changed from active, no longer recruiting to completed.
- 20 May 2022 This trial has been completed in Denmark, according to European Clinical Trials Database record.
- 30 Nov 2021 Planned End Date changed from 1 Oct 2021 to 1 Jul 2022.